Emcure Pharmaceuticals Ltd on Tuesday (Nov 11) reported a 25.1% year-on-year rise in consolidated net profit to ₹243 crore for the quarter ended September 2025, compared with ₹194 crore in the same period last year.

Revenue from operations grew 13.4% year-on-year to ₹2,269.8 crore from ₹2,001.9 crore in Q2 FY25, driven by strong growth across key therapeutic segments and continued momentum in both domestic and international markets.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) rose 25% to ₹475.4 crore from ₹380.3 crore in the year-ago quarter, while EBITDA margin improved to 21% from 19% a year earlier, aided by better product mix and cost efficiencies.

The company said its performance reflected robust traction in its India formulations business and healthy ex

See Full Page